Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...

The partnership brings together Pfizer’s scientific data and therapeutic expertise with Boltz’s open-source AI foundation ...

Pfizer is penning a cancer discovery pact with Cartography Biosciences that could max out at $865 million biobucks. | Pfizer ...

Now, it’s worth noting Stock Advisor’s total average return is 971 % — a market-crushing outperformance compared to 196% for ...

Pfizer recently announced its guidance for 2026. One thing seems clear: Its financial results won't get much stronger. It ...

Pfizer (PFE) stock has attracted fresh attention after recent trading left its one-month return at a 3.3% decline and its ...

Pfizer Inc. and Boltz, PBC, an applied AI research lab, today announced a strategic collaboration to empower scientists ...

Let’s dive into details regarding each of the evaluated factors, but first, for quick context: With $143 Bil in market capitalization, Pfizer offers biopharmaceutical products which include ...

Bayer's Monsanto sued COVID-19 vaccine makers Pfizer, BioNTech and Moderna in Delaware federal court ​on Tuesday for ...

Pfizer's 2026 revenue midpoint of $61B and EPS midpoint of $2.90 decline YoY, reflecting persisting headwinds. Read more on ...

A patient died after receiving Pfizer Inc.’s drug for hemophilia, marking another setback for the company in the treatment of blood disorders.

Investing $12,000 in the stock today would allow you to collect approximately $600 in dividends per year. Combined with the ...